SMARCA4 and neoplasm: SMARCA4/2 inhibition with FHD-286 monotherapy slightly decreased tumor growth in all models tested; in contrast, the combination of FHD-286 with afatinib induced strong growth-suppressive responses in all models assessed (Figs. 6H and S8F).